Latest News

View All Recent News »

Alimera Sciences Added to NASDAQ Biotechnology Index

December 16, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has been added to the NASDAQ Biotechnology Index...

Read More »

Alimera Sciences Announces Closing of $50.0 Million Financing with Deerfield Management

December 15, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has closed its offering of Series B Preferred...

Read More »

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In The Netherlands For The Treatment Of Chronic Diabetic Macular Edema

December 01, 2014 -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Dutch Inspectie voor de Gezondheidszorg (IGZ) has...

Read More »